1st Oct 2015 12:05
Immunodiagnostic Systems Holdings PLC
Total Voting Rights
1 October 2015
In accordance with Disclosure and Transparency Rule 5.6.1, the issued share capital of Immunodiagnostic Systems Holdings plc as at 30 September 2015 comprises 29,415,175 ordinary shares of 2p each with voting rights. There are no shares held in treasury.
The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.
For further information:
Immunodiagnostic Systems Holdings plc | Tel : +44 (0)191 519 0660 |
Patricio Lacalle, Chief Executive Officer
| |
Peel Hunt LLP | Tel : +44 (0)207 418 8900 |
James Steel Oliver Jackson |
About Immunodiagnostic Systems Holdings PLC:
The Group's vision is to be a leading solution provider to the clinical laboratory diagnostic market. IDS's strategy is focused on developing, internally and through partnership, its automated assay menu for its proprietary automated immunoassay analyser, the IDS-iSYS system. Internally the Group is focused on developing an endocrinology excellence menu and externally IDS works with partners to develop assay panels in complementary indication fields. The Group sells its products primarily in the clinical laboratory market across a range of customers from reference laboratories to physician office laboratories. IDS has field sales forces in certain European countries, including France and Germany, the United States and Brazil and works with distributors in other markets including China, Italy and Spain.
Related Shares:
IDH.L